Metabolic · Amylin receptor agonist
Cagrilintide
- Drug class
- Amylin receptor agonist
- Status
- Compounded (503A)
- Also known as
- AM833, CagriSema (combination)
- Reviewed
- 2026-06-01 · Kindr Health Clinical Team
What Cagrilintide is studied for
- Chronic weight management (with or without semaglutide)
- Appetite regulation and satiety
- CagriSema combination therapy (phase 3)
Mechanism of action
Long-acting analog of human amylin (pramlintide-class). Activates amylin receptors in the hindbrain to slow gastric emptying, suppress glucagon, and increase satiety — complementary to GLP-1 pathways.
Frequently asked questions
What is CagriSema?
CagriSema is the fixed-dose combination of cagrilintide + semaglutide (Novo Nordisk). Phase 3 REDEFINE trials report ~20–22% average weight loss, exceeding semaglutide alone.
Is cagrilintide available on its own?
It is not yet FDA-approved as a stand-alone product. Phase 3 trials are ongoing; expected regulatory submission 2026–2027.
Side effects?
Similar GI profile to other incretins — nausea, vomiting, diarrhea — generally well tolerated when titrated.
Build the Cagrilintide protocol stack
Research protocols commonly pair Cagrilintide with the peptides below. Add all three vials to unlock the bundle discount at checkout.
Related peptides in Metabolic
Continue across the Kindr entity graph
Related evidence, peptides, and clinical tools on the same topic.
- GLP-1s in menopauseJournal
- Menopause & weight gainJournal
- SemaglutidePeptide
- TirzepatidePeptide
- GLP-1 weight care serviceMedication
